Back to Screener

Healthcare

Sona Nanotech Inc.(SNANF)

Live Price

Offline

$0.201

+0.00% today

1Y Change

-29.34%

Window

Jun 20, 2025 โ†’ May 29, 2026

Market Cap
$40.00M
Revenue Growth
0.0%
EPS Growth
-7.4%
Dividend Yield
0.0%

Coverage: 237 bars ยท Jun 20, 2025 โ†’ May 29, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Sona Nanotech Inc. (SNANF) is a Healthcare stock with a market cap of $40.00M and listed on OTC. The stock last traded around $0.20 and down 29.3% across the available one-year price window (Jun 20, 2025 โ†’ May 29, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -7.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -7.4%, free cash flow -0.1% with operating margin 0.0% and ROIC -1878.2%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SNANF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Below sector median

0.0% vs +7.6% peer median

Operating Margin

Below sector median

0.0% vs +19.4% peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report landed above expectations

2026 was reported on Apr 2, 2026 with an EPS surprise of +28.2%.

The operating picture looks softer than before

Revenue is at 0.0% and EPS is at -7.4%, with operating margin around 0.0%.

The next real check-in already has a date

The next earnings event is scheduled for Jun 25, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.

Earnings Reaction Memory

How the stock has tended to move after recent reports.

Across the last 3 reported quarters, the stock averaged -5.5% over the next 5 trading days and finished higher after 0 of those reports.

View quarter-by-quarter reaction table
QuarterEPS ฮ”1D5D20D
2026
Apr 2, 2026
+28.2%-4.7%-1.3%-5.5%
2026
Feb 25, 2026
+64.8%+0.0%-10.2%-26.8%
2025
Sep 25, 2025
+42.3%-1.8%-5.1%+6.3%

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

SNANF

โ€”

Normalized return

SPY

โ€”

S&P 500

Excess Return

โ€”

Relative to SPY

SNANF Max Drawdown

-61.71%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for SNANF and SPY.

Calendar-year return history is still loading or unavailable.
Sona Nanotech Inc. logo

Company Overview

Sona Nanotech Inc.

Other OTC

Halifax, NS, CA
Visit sonanano.comCall IR902-442-0653

Sona Nanotech Inc., nanotechnology life sciences company, manufactures and sells gold nanorod products for diagnostic tests. The company also provides Nanotech COVID-19 Lateral Flow Assay, an immunochromatographic assay for the detection of the spike protein antigen from SARS-CoV-2 in saliva specimens from individuals, who are suspected of COVID-19; Gemini gold nanorods; Omni gold nanorods for medical applications; and contract services. Its products are used in various applications, including drug delivery, food and beverage testing, environmental testing, cell imaging, cancer treatment, and liposuction therapy, as well as medical and consumer, military, and veterinary diagnostics. The company is based in Halifax, Canada.

Leadership
David Andrew Regan
IPO Date
Jul 27, 2006
Employees
8
Street Address
Purdyโ€™s Wharf Tower II
Mailing
Halifax, NS, B3J 3R7
Region
Halifax, NS, CA
Reporting Currency
USD
Investor Line
902-442-0653
Last Updated
May 4, 2026
ISIN: CA83541C1059
Reports in USD

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
โ€”
EV/EBITDA
โ€”
Price/Sales
โ€”
Price/Book
โ€”

Growth

Revenue
0.0%
EPS
-7.4%
Free Cash Flow
-0.1%

Profitability

Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-1043.0%
ROIC
-1878.2%

Balance Sheet

Debt/Equity
โ€”
Current Ratio
0.20

Earnings Reports

๐Ÿ“… Next earningsJun 25, 2026
PeriodB/MEPSEPS ฮ”RevenueRev ฮ”
โ€”
Jun 25, 26
TBD
โ€”
Est -0.01
โ€”
โ€”
Est โ€”
โ€”
โ€”
Apr 2, 26
โœ“
-0.01
Est -0.01
+28.2%
โ€”
Est โ€”
โ€”
โ€”
Feb 25, 26
โœ“
-0.00
Est -0.01
+64.8%
โ€”
Est โ€”
โ€”
โ€”
Sep 25, 25
โœ“
-0.01
Est -0.01
+42.3%
โ€”
Est โ€”
โ€”
โ€”
Jun 27, 25
โœ“
-0.01
Est -0.01
+43.8%
โ€”
Est โ€”
โ€”
โ€”
Mar 31, 25
-0.01
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Oct 31, 24
-0.00
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Jul 31, 24
-0.01
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Apr 30, 24
-0.01
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Apr 26, 24
-0.01
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Oct 31, 23
-0.01
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Jul 31, 23
-0.01
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Apr 30, 23
-0.00
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Jan 31, 23
-0.00
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Oct 31, 22
0.01
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Jul 31, 22
-0.01
Est โ€”
โ€”
โ€”
Est โ€”
โ€”

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.

Explore the advanced chart guideRead how to compare stocks